Thursday's Analysts' Upgrades and Downgrades - TheStreet

Thursday's Analysts' Upgrades and Downgrades

Who made what calls.
Author:
Publish date:

CHANGE IN RATINGS

Goldcorp

(GG)

upgraded at Prudential to Neutral from Underweight. $27 price target. Estimates also raised to reflect higher gold prices.

Invitrogen

(IVGN)

downgraded at JP Morgan from Overweight to Neutral. Current restructuring plan will take several quarters.

National Semi

(NSM)

upgraded at Morgan Stanley from equalweight to overweight and raises price target from $26 to $31.

Valueclick

(VCLK)

downgraded at Oppenheimer from Buy to Neutral. Stock has reached the $30 price target, and upside could be limited with flat margins expected for 2007.

Waters

(WAT) - Get Report

downgraded at JP Morgan from Overweight to Neutral. Valuation call, as the fundamental thesis remains intact.

Whole Foods

(WFMI)

upgraded at UBS to Buy rating from Neutral, UBS said. Price target jumps to $60 from $50. 2008 EPS estimates rise to $1.85 from $1.75.

STOCK COMMENTS / EPS CHANGES

E*Trade Financial

(ETFC) - Get Report

initiated at UBS with Buy rating. Price target set at $29 and FY07 EPS estimates start at $1.72.

Hewlett-Packard

(HPQ) - Get Report

target raised at Goldman. Goldman said it is upping its target on HPQ to $50 from $48 after the company reported 10% top line growth and topped earnings expectations. 2007 estimates increased to $2.65 from $2.57. Maintained Buy rating.

MetLife

(MET) - Get Report

target price raised at Credit Suisse. Credit Suisse said it is raising its target price on MET to $71 from $65 based on continued upward EPS revisions. Maintained Outperform rating.

MedcoHealth

(MHS)

target price raised at Credit Suisse. It is raising its target price on MHS to $71 from $55 following strong Q4 results and positive guidance. Maintained Neutral rating.

WebMD

(WBMD)

price target increased at Goldman to $52 from $44. Q4 results featured accelerating organic growth of 42$ year over year. Also noted strong EBITDA outlook for 2007 -- 10% above consensus estimates. Maintained Neutral rating.